 |
5 Diseases |  |
64 Trials |
|
64 Trials |  |
4136 News |  |
| «12345678910111213...6162» |
- | risperidone / Generic mfg.
Journal: Efficacy and Safety of Risperidone in Patients With Delirium: The RIDDLE Pilot Study. (Pubmed Central) - Dec 18, 2023
Future large-scale trials are needed to evaluate the safety and efficacy of risperidone in the treatment of delirium. This pilot study taught us that the phase 2 RIsperDone DELirium trial will need a multicenter design with more research personnel to increase the number of participants enrolled.
- | Retrospective data, Journal: Use of Psychotropic Drugs during the COVID-19 pandemic in Minas Gerais, Brazil. (Pubmed Central) - Dec 17, 2023
This pilot study taught us that the phase 2 RIsperDone DELirium trial will need a multicenter design with more research personnel to increase the number of participants enrolled. The change in the psychotropic drug dispensation profile during the COVID-19 pandemic highlights the need to produce more studies to complete, confirm or rule out this profile and monitor the use of psychotropic drugs by the population in the post-pandemic context.
- | risperidone / Generic mfg.
Journal: Neural EGFL-like 1, a craniosynostosis-related osteochondrogenic molecule, strikingly associates with neurodevelopmental pathologies. (Pubmed Central) - Dec 16, 2023
Interestingly, Nell-1 mice demonstrated core autism spectrum disorder-like deficits, which could be corrected by Risperidone, an FDA-approved anti-autism, anti-bipolar medicine...Moreover, this study opens new avenues for understanding and treating craniofacial patients suffering from skeletal deformities and behavior, memory, and cognition difficulties by uncovering a novel bone-brain-crosstalk network. Furthermore, the transcriptomic analysis provides the first insight into deciphering the mechanism of Nell-1 in neurodevelopment.
- || ulotaront (SEP-363856) / Sumitomo Pharma, Otsuka, PsychoGenics
Trial completion date, Trial primary completion date: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia (clinicaltrials.gov) - Dec 15, 2023
P1, N=60, Recruiting, Sponsor: Sumitomo Pharma America, Inc.
Furthermore, the transcriptomic analysis provides the first insight into deciphering the mechanism of Nell-1 in neurodevelopment. Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Oct 2023 --> Mar 2024
- | Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series. (Pubmed Central) - Dec 13, 2023
Failure to a first AA-augmentation trial does not preclude response to a second one. This preliminary result requires confirmation through more rigorous studies conducted over greater samples.
- | risperidone / Generic mfg.
Journal: Resolving the Dance: A Case Study on Non-Ketotic Hyperglycemic Hemichorea-Hemiballismus in a Patient with Long-Standing Type 2 Diabetes. (Pubmed Central) - Dec 8, 2023
Treatment entails tight blood glucose control, although antipsychotic medications such as risperidone may be helpful in refractory cases...Patients with long-standing type 2 diabetes may be affected, especially when glycemic control worsens. When tight blood glucose control does not resolve symptoms, a short course of antipsychotic agents may provide relief.
- || risperidone / Generic mfg.
Clinical, Journal: Therapeutic Impacts of Hyperbaric Oxygen Therapy and Risperidone on Children with Autism: A Clinical Trial. (Pubmed Central) - Dec 5, 2023
The current study assessed the therapeutic effect of hyperbaric oxygen therapy and risperidone on the core symptoms of autism. The results revealed that both hyperbaric oxygen therapy and risperidone reduced the core symptoms of autism, but hyperbaric oxygen therapy gave better therapeutic results than risperidone.
- || risperidone / Generic mfg.
PK/PD data, Journal: The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism. (Pubmed Central) - Dec 2, 2023
The study confirmed the previously reported partial impact of the CYP2D6 gene on RIS PK. However, future studies using contemporary genotyping techniques targeting a wide range of variants in other candidate genes must be conducted to further examine their interactive effects on RIS PK and the clinical response.
- | risperidone / Generic mfg.
Journal: Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. (Pubmed Central) - Nov 30, 2023
Logistic regression analysis showed that the therapeutic effect and adverse reactions of RIS were correlated with the ratio of C/D in patients with schizophrenia (P?=?0.038; P?<?0.001). It has been suggested that the importance of monitoring of the plasma concentration of RIS in patients with schizophrenia and the ratio of C/D may be used as the reference for RIS personalized treatment.
- | risperidone / Generic mfg.
Journal: Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder. (Pubmed Central) - Nov 29, 2023
It has been suggested that the importance of monitoring of the plasma concentration of RIS in patients with schizophrenia and the ratio of C/D may be used as the reference for RIS personalized treatment. TDM may be a useful tool for optimizing risperidone treatment in children and adolescents with autism spectrum disorder.
- || Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Review, Journal: Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. (Pubmed Central) - Nov 29, 2023
TDM may be a useful tool for optimizing risperidone treatment in children and adolescents with autism spectrum disorder. Molecular neuroimaging studies serve as a strong tool for defining target ranges for antipsychotic drug treatment and directing therapeutic drug monitoring.
- | risperidone / Generic mfg., clozapine / Generic mfg.
Journal: Therapeutic Drug Level Monitoring of Antipsychotics at an Inpatient Psychiatric Hospital. (Pubmed Central) - Nov 29, 2023
Although more patients were prescribed risperidone, clozapine had the highest TDM rate. Clinicians were more likely to keep antipsychotic regimens unchanged for appropriately drawn levels and adjust doses for inappropriately drawn levels.
- | risperidone / Generic mfg.
Journal: Oculogyric crisis symptoms related to risperidone treatment: a case report. (Pubmed Central) - Nov 29, 2023
Oculogyric crisis (OGC) is a rare focal dystonia of the oculogyric muscle. This case provides clinicians with a basis for the early recognition and management of oculogyric crisis during the use of atypical antipsychotics (risperidone).
- | risperidone / Generic mfg., olanzapine / Generic mfg.
Journal: Hyperleptinemia contributes to antipsychotic drug-associated obesity and metabolic disorders. (Pubmed Central) - Nov 27, 2023
We conclude that hyperleptinemia is a key contributor to antipsychotic drug-associated weight gain and metabolic deterioration. Leptin suppression may be an effective approach to reducing the undesirable side effects of antipsychotic drugs.
- | risperidone / Generic mfg.
Journal: Association of Prolactin, Oxytocin and Homocysteine with the clinical and cognitive features of a First Episode of Psychosis over a 1-year follow-up. (Pubmed Central) - Nov 27, 2023
Leptin suppression may be an effective approach to reducing the undesirable side effects of antipsychotic drugs. This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.
- ||| Trintellix (vortioxetine) / Lundbeck, Takeda
Journal, Adverse events: Drugs and bruxism: a study in the World Health Organization's pharmacovigilance database. (Pubmed Central) - Nov 27, 2023
A signal was also described for oxybate sodium and metoclopramide. For antidepressants, a negative association was found between ROR values and NET (norepinephrine transporter) but not SERT (serotonin transporter) pKi values, suggesting this ADR is more closely linked to norepinephrine than serotonin reuptake inhibition.
- | MK-8189 / Merck (MSD)
Phase classification: Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (clinicaltrials.gov) - Nov 27, 2023
P2, N=500, Recruiting, Sponsor: Merck Sharp & Dohme LLC
For antidepressants, a negative association was found between ROR values and NET (norepinephrine transporter) but not SERT (serotonin transporter) pKi values, suggesting this ADR is more closely linked to norepinephrine than serotonin reuptake inhibition. Phase classification: P2b --> P2
- | risperidone / Generic mfg.
Preclinical, Journal: Tailoring Risperidone-Loaded Glycethosomal In Situ Gels Using Box-Behnken Design for Treatment of Schizophrenia-Induced Rats via Intranasal Route. (Pubmed Central) - Nov 25, 2023
Following biochemical assessments of schizophrenia-induced rats, the optimized gel boosted the neuroprotective, anti-oxidant, and anti-inflammatory action of RS in comparison to other tested preparations. Collectively, the intranasal RS-loaded glycethosomal gel offered a potential substitute to oral therapy for schizophrenic patients.
- || Review, Journal, HEOR: Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient's Subjective Quality of Life, Well-Being, and Satisfaction. (Pubmed Central) - Nov 25, 2023
Although promising, the evidence is still limited because of the lack of studies and several methodological issues concerning the choice of the sample, the evaluation of the outcome variables, and the study design. New methodologically sound studies are needed.
- || clozapine / Generic mfg.
Review, Journal: Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review. (Pubmed Central) - Nov 22, 2023
This preliminary evidence suggests clinical utility of LAIs in alleviating residual symptoms and subsequently reducing hospitalisation rates in patients optimised on clozapine treatment. The current study warrants further investigations including a randomised controlled study to establish the clinical efficacy, tolerability, and place in therapy of this treatment modality.
- || Retrospective data, Review, Journal: Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis. (Pubmed Central) - Nov 21, 2023
Olanzapine caused less discontinuation than quetiapine; quetiapine caused less discontinuation than ziprasidone, aripiprazole and haloperidol; ziprasidone caused less discontinuation than quetiapine, aripiprazole and haloperidol; aripiprazole caused less discontinuation than quetiapine, ziprasidone and olanzapine and olanzapine caused less discontinuation than ziprasidone and haloperidol (p < 0.05). It was concluded that individual patient clinical response, tolerance to side effects and life-threatening side effects remain the most reliable basis for selecting and continuing the use of APD.
- | risperidone / Generic mfg., oxazepam / Generic mfg., ibuprofen / Generic mfg.
Journal: Potentially Inadequate Medications in the Elderly: PRISCUS 2.0-First Update of the PRISCUS List. (Pubmed Central) - Nov 21, 2023
It was concluded that individual patient clinical response, tolerance to side effects and life-threatening side effects remain the most reliable basis for selecting and continuing the use of APD. The new, greatly extended PRISCUS list must now be validated in epidemiological and prospective studies and itspracticability in routine daily use must be verified.
- | risperidone / Generic mfg.
Journal: More options, more value: a new long-acting injectable formulation of risperidone. (Pubmed Central) - Nov 20, 2023
The new, greatly extended PRISCUS list must now be validated in epidemiological and prospective studies and itspracticability in routine daily use must be verified. No abstract available
- | Journal: Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society). (Pubmed Central) - Nov 16, 2023
No abstract available Since most HD patients simultaneously suffer from distinct motor signs and distinct psychiatric/behavioral symptoms, treatment should be individually adapted.
- risperidone / Generic mfg.
Withdrawn Catatonia Mimicking a Cerebrovascular Accident: A Story of Diagnosis () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_706;
Several characteristics of catatonia mimic symptoms of pathologies including CVAs. Understanding of these symptoms can guide differentiation of thorough workup versus prompt treatment.
- risperidone / Generic mfg.
Treatment of an Uncommon Case of Isolated Hemichorea After Caudate Head Stroke: A Case Report () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_482;
Isolated hemichorea is an uncommon post-stroke movement disorder that often displays spontaneous remission. In severe cases, patients may benefit from pharmacological treatment using atypical neuroleptic agents.
- || risperidone / Generic mfg.
Clinical, Journal: L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial. (Pubmed Central) - Nov 13, 2023
In severe cases, patients may benefit from pharmacological treatment using atypical neuroleptic agents. L-Theanine adjunct to risperidone safely and tolerably outperformed adjunctive placebo for schizophrenia, and promising evidence indicated its effects on primary negative symptoms, which need to be scrutinized in further studies.
- | Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Retrospective data, Journal: Single trajectory treatment response for predominant negative symptoms: Post-hoc analysis of a clinical trial with cariprazine and risperidone. (Pubmed Central) - Nov 13, 2023
Results demonstrated that in comparison with competing models, a single trajectory best described the treatment response of patients with predominant negative symptoms. The results indicate that patients with predominant negative symptoms with over ten years of schizophrenia respond rapidly to adequate treatment and follow a course of steady improvement.
- | aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
New trial: The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset (clinicaltrials.gov) - Nov 13, 2023
P=N/A, N=300, Not yet recruiting, Sponsor: Peking University
- | Retrospective data, Journal: On- and off-label utilisation of antipsychotics in Australia (2000-2021): Retrospective analysis of two medication datasets. (Pubmed Central) - Nov 9, 2023
The most commonly prescribed antipsychotics were quetiapine, olanzapine and risperidone, with a significant portion of patients receiving low-dose quetiapine without dose titration...The increasing prescribing and off-label use highlights concerns about chronic adverse effects caused by antipsychotics. The combined analysis of medication dispensings and the diagnostic indications for which they are prescribed is a novel approach and throws a spotlight on the need for additional monitoring of antipsychotics.
- | risperidone / Generic mfg.
Trial completion: Electrical Brain Stimulation and Pharmacological Treatments in Autism Spectrum Disorder (clinicaltrials.gov) - Nov 7, 2023
P1, N=45, Completed, Sponsor: The National Brain Mapping Laboratory (NBML)
The combined analysis of medication dispensings and the diagnostic indications for which they are prescribed is a novel approach and throws a spotlight on the need for additional monitoring of antipsychotics. Active, not recruiting --> Completed
- || risperidone / Generic mfg., blonanserin / Generic mfg.
Retrospective data, Review, Journal: Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 3, 2023
The efficacy of blonanserin is similar to that of risperidone, but it is unclear whether blonanserin is more effective than risperidone at improving cognitive and social function. More high-quality studies are needed to verify the efficacy and safety of blonanserin in the future.
- | risperidone / Generic mfg., carbamazepine / Generic mfg.
Journal: Drugs prescribed for Phelan-McDermid syndrome differentially impact sensory behaviors in shank3 zebrafish models. (Pubmed Central) - Nov 3, 2023
Finally, shank3 mutants showed resistance to the seizure-inducing drug pentylenetetrazol (PTZ), at a dosage that results in hyperactive swimming in WT zebrafish. Our work shows that the effects of drugs on sensory processing are varied in ways that can be highly genotype- and drug-dependent.
- risperidone / Generic mfg., ketamine / Generic mfg.
Functional in vitro Screening of 5-HT2A receptor modulators in neuronal network cultures (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_10701;
5-HT2A agonists exhibit a rapid effect in the CNS with a strong afterward desensitization, which is challenging for in vitro modeling.We have tested 5-HT2A modulators in our microelectrode array approach on primary frontal cortex cultures from mice cultivated 28 days in vitro, such as risperidone, DOI, DMT, MDMA, and psilocin...We found a significantly different behavior in these time intervals.Our experiments showed that psychedelics show a strong variation of activity in the first hours of application. The time course of the dose responses could be a clear descriptive biomarker for assessing psychedelics and potentially anti-depressive compounds.
- aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
A REVIEW: INVESTIGATION OF THE ROLE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE FORMATION OF METABOLIC SYNDROME AND SYSTEMATIC LITERATURE REVIEW OF THE RELATIONSHIP BETWEEN SEROTONERGIC GENE TYPES. (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5531;
In addition to the search engines, we will use in the literature review, theses, compilationarticles, bibliographies, manual searches in related journals, reports and bibliographies werescanned. The data, which we obtained using Boolean and fuzzy logic methods, are onlyquantitative studies and those whose publication language is English and between 1990 and2022 were selected.Keywords: We chose to conduct this study are Drug Interactions, HTR2A, MetabolicSyndrome, Schizophrenia were figured out as.
- risperidone / Generic mfg.
Mice treated with risperidone during the juvenile period have long term effects on social memory and PFC neuronal activity in adulthood (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_5530;
Taken together, our results suggest that adolescent risperidone treatment may induce long-term changes in social memory and anxiety levels, associated with altered neuronal activity in the frontal cortex. Our results, while preliminary, may offer additional consideration in off-label treatment of adolescents with antipsychotics and for the possible relevance of sex differences in these effects.
- risperidone / Generic mfg.
Mice treated with risperidone during the juvenile period sustain long term changes in social memory and PFC neuronal activity in adulthood (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_4477;
Taken together, our results suggest that adolescent risperidone treatment may induce long-term changes in social memory and anxiety levels, associated with altered neuronal activity in the frontal cortex. Our results, while preliminary, may offer additional consideration in off-label treatment of adolescents with antipsychotics and suggest a possible relevance of sex differences in these effects.
- Second-Generation Antipsychotics and VTE Risk (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5444;
Our results, while preliminary, may offer additional consideration in off-label treatment of adolescents with antipsychotics and suggest a possible relevance of sex differences in these effects. Events were then narrowed further to include only those associated with a single second-generation antipsychotic
- | risperidone / Generic mfg., amoxicillin / Generic mfg.
Journal: Top 5 Research Studies of the month for Italian Primary Care Physicians: October 2023. (Pubmed Central) - Oct 30, 2023
According to a good quality systematic review and network meta-analysis, only a small number of randomized controlled trials, disappointing in overall quality, suggest that for managing neuropsychiatric symptoms in adults with dementia, risperidone has the best balance of effectiveness and adverse effects...In a large study of more than 21,000 participants aged 60 to 84 years, taking 60,000 IU vitamin D each month slightly reduced their likelihood of experiencing a major cardiovascular event (number needed to treat = 172 over 5 years). A single screening colonoscopy had higher rates of participation than 5 years of fecal occult blood testing in a high-quality study in which patients were offered free screening with these two methods (84% vs 73%; p<0.001).
- | Journal, Real-world evidence, Real-world: Lower Risks of Gastrointestinal Perforation and Intestinal Obstruction in Patients with Atypical Antipsychotics in Comparison with Typical Antipsychotics Based on Real-World Data from the MID-NET in Japan. (Pubmed Central) - Oct 30, 2023
In addition, no major differences in the risks of atypical antipsychotics, such as risperidone, quetiapine, olanzapine, and aripiprazole, were identified in this study. The safety profile regarding the lower risks of gastrointestinal perforation and intestinal obstruction in patients prescribed atypical antipsychotics should be considered when choosing antipsychotics in clinical practice in terms of the proper use of such drugs.
- | risperidone / Generic mfg., donepezil / Generic mfg., paroxetine / Generic mfg.
Preclinical, Journal: Sexually Dimorphic Effects of Neuromodulatory Drugs on Normal and Stress-Induced Social Interaction in Rats. (Pubmed Central) - Oct 28, 2023
The study showed a predominant effect of Risperidone on males while there were differential effects of Donepezil and Paroxetine on both sexes. This study has paved the way for the development of more targeted and effective neuromodulatory drugs for use against various psychiatric and social deficits.
- | risperidone / Generic mfg.
Journal: Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies. (Pubmed Central) - Oct 27, 2023
Although some medications like risperidone show potential in regulating ASD-associated symptoms, a comprehensive treatment strategy for ASD is yet to be discovered...A novel systematic and personalized treatment approach is suggested, combining the available medications and targeting each symptom accordingly. Herein, summarize and categorize the most appropriate ways of modern ASD management into three distinct categories: current, promising, and prospective strategies.
- | aripiprazole / Generic mfg., risperidone / Generic mfg., olanzapine / Generic mfg.
Journal: Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom. (Pubmed Central) - Oct 27, 2023
It was concluded that olanzapine, risperidone and aripiprazole are the most commonly selected as the initial treatment choice by psychiatrists from India and the UK. They are perceived as widely effective and well tolerated.
- || risperidone / Generic mfg.
Review: BDNF gene Val66Met polymorphisms as a predictor for clinical presentation in schizophrenia - recent findings. (Pubmed Central) - Oct 27, 2023
However, due to heterogeneous results, the diversity in study populations and studies' small sample sizes, generalizations cannot be made. Our findings emphasize the need for further research dedicated to clarifying the role of gene polymorphisms in antipsychotic treatment to enhance specificity and efficacy in the treatment of schizophrenia.
- || Nuplazid (pimavanserin) / Acadia Pharma
Retrospective data, Review, Journal: Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis. (Pubmed Central) - Oct 23, 2023
In patients with PDP, pimavanserin and clozapine demonstrated significant improvement in psychosis without affecting motor function. With quetiapine being associated with a significant decline in cognition and despite not impairing motor function, our findings suggest that it should be avoided in patients with PDP and reduced cognitive abilities.
- | aripiprazole / Generic mfg., risperidone / Generic mfg.
Journal: Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis. (Pubmed Central) - Oct 20, 2023
Adolescents hospitalized for co-occurring psychosis and cannabis use disorder had a significantly longer length of stay and length of stay index. These data are consistent with a more rapid reduction in acute psychotic symptoms for aripiprazole compared with risperidone in the context of co-occurring cannabis use disorder.
- || Clinical data, Journal: Prolactin Level Changes according to Atypical Antipsychotics Use: A Study Based on Clinical Data Warehouse. (Pubmed Central) - Oct 20, 2023
And we showed that there is a possibility to conduct more effective and simpler big data research using the CDW. Further studies on the subjects with controlled confounding variables and larger sample groups are needed.
- | risperidone / Generic mfg.
Journal: Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study. (Pubmed Central) - Oct 20, 2023
Our study suggested that smoking affected the severity of baseline negative symptoms and further contributed to their reduction after risperidone treatment. However, improvement in negative symptoms was not dependent on the changes in TAOC.
- | Journal, Real-world evidence, Real-world: Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data. (Pubmed Central) - Oct 15, 2023
However, lithium use led to fewer reports of severe weight gain than some alternative drugs for long-term medication (olanzapine, quetiapine, and valproate), which is consistent with recent studies. Monitoring of weight gain and metabolic parameters remains essential with lithium and its alternatives.
- | risperidone / Generic mfg., clozapine / Generic mfg.
Preclinical, Journal: The Nitric Oxide (NO) Donor Molsidomine Attenuates Memory Impairments Induced by the D1/D2 Dopaminergic Receptor Agonist Apomorphine in the Rat. (Pubmed Central) - Oct 14, 2023
The present findings propose that molsidomine is sensitive to DA dysregulation since it attenuates memory deficits induced by apomorphine. Further, the current findings reinforce the potential of molsidomine as a complementary molecule for the treatment of schizophrenia.